Prognosis and immune landscape of bladder cancer can be predicted using a novel miRNA signature associated with cuproptosis

Background Bladder cancer is characterized by a high recurrence rate and mortality, posing a significant challenge to clinical management. Recently, cuproptosis, a novel form of regulated cell death, has been identified as a potential target for therapeutic intervention in various diseases. The cont...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhilei Zhang, Fang Liu, Yongbo Yu, Fei Xie, Tao Zhu
Format: Article
Language:English
Published: PeerJ Inc. 2024-11-01
Series:PeerJ
Subjects:
Online Access:https://peerj.com/articles/18530.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846147300015996928
author Zhilei Zhang
Fang Liu
Yongbo Yu
Fei Xie
Tao Zhu
author_facet Zhilei Zhang
Fang Liu
Yongbo Yu
Fei Xie
Tao Zhu
author_sort Zhilei Zhang
collection DOAJ
description Background Bladder cancer is characterized by a high recurrence rate and mortality, posing a significant challenge to clinical management. Recently, cuproptosis, a novel form of regulated cell death, has been identified as a potential target for therapeutic intervention in various diseases. The contribution of cuproptosis-related microRNAs (miRNAs) in bladder cancer pathogenesis, however, remains largely unexplored. Therefore, the current study aims to construct a miRNA signature related to cuproptosis for predicting the prognosis and facilitating personalized therapeutic strategies in bladder cancer patients. Methods In this study, we retrieved transcriptomic data and clinical information pertaining to bladder cancer from publicly available databases, including the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). We identified a set of 19 cuproptosis-related genes through a comprehensive review of relevant literature. Using multivariate Cox regression and LASSO analysis, we constructed a cuproptosis-related miRNA prognostic signature. The Kaplan-Meier (K-M) and receiver operating characteristic (ROC) curves were used to validate the accuracy of prediction. Additionally, we developed a nomogram incorporating clinical characteristics and the miRNA signature to further assess its prognostic value. We evaluated the tumor microenvironment (TME) of every patient using immune ESTIMATE, CIBERSORT, and ssGSEA algorithms. We also investigated the differences in tumor mutation burden (TMB) and drug sensitivity between two groups. Finally, we validated the prognostic value of this miRNA signature using the OncomiR dataset. Results We developed a panel of eight cuproptosis-associated miRNAs to serve as a prognostic signature. The predictive validity of this signature was determined using Kaplan-Meier and ROC curves, and was found to be acceptable in both the TCGA training, test and total dataset. The prognostic value of this signature was confirmed by univariate and multivariate Cox regression analysis, indicating its applicability as a prognostic factor. The immune cell infiltration was significantly associated with an immunosuppressive phenotype of TME in the high-risk group of patients; meanwhile, patients in the high-risk group had a lower TMB resulted in shorter survival. Notably, higher estimate scores and IC50 value for chemotherapy drugs were observed in the high-risk group, indicating poor response to immune therapy and chemotherapy.
format Article
id doaj-art-f404df42d4d84bfd992be1bfd8fce77f
institution Kabale University
issn 2167-8359
language English
publishDate 2024-11-01
publisher PeerJ Inc.
record_format Article
series PeerJ
spelling doaj-art-f404df42d4d84bfd992be1bfd8fce77f2024-12-01T15:05:31ZengPeerJ Inc.PeerJ2167-83592024-11-0112e1853010.7717/peerj.18530Prognosis and immune landscape of bladder cancer can be predicted using a novel miRNA signature associated with cuproptosisZhilei Zhang0Fang Liu1Yongbo Yu2Fei Xie3Tao Zhu4The Department of Urology, The First Affiliated Hospital of Shandong Second Medical University, Weifang, ChinaThe Department of Cardiology, The First Affiliated Hospital of Shandong Second Medical University, Weifang, ChinaThe Department of Urology, The First Affiliated Hospital of Shandong Second Medical University, Weifang, ChinaThe Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, ChinaThe Department of Urology, The First Affiliated Hospital of Shandong Second Medical University, Weifang, ChinaBackground Bladder cancer is characterized by a high recurrence rate and mortality, posing a significant challenge to clinical management. Recently, cuproptosis, a novel form of regulated cell death, has been identified as a potential target for therapeutic intervention in various diseases. The contribution of cuproptosis-related microRNAs (miRNAs) in bladder cancer pathogenesis, however, remains largely unexplored. Therefore, the current study aims to construct a miRNA signature related to cuproptosis for predicting the prognosis and facilitating personalized therapeutic strategies in bladder cancer patients. Methods In this study, we retrieved transcriptomic data and clinical information pertaining to bladder cancer from publicly available databases, including the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). We identified a set of 19 cuproptosis-related genes through a comprehensive review of relevant literature. Using multivariate Cox regression and LASSO analysis, we constructed a cuproptosis-related miRNA prognostic signature. The Kaplan-Meier (K-M) and receiver operating characteristic (ROC) curves were used to validate the accuracy of prediction. Additionally, we developed a nomogram incorporating clinical characteristics and the miRNA signature to further assess its prognostic value. We evaluated the tumor microenvironment (TME) of every patient using immune ESTIMATE, CIBERSORT, and ssGSEA algorithms. We also investigated the differences in tumor mutation burden (TMB) and drug sensitivity between two groups. Finally, we validated the prognostic value of this miRNA signature using the OncomiR dataset. Results We developed a panel of eight cuproptosis-associated miRNAs to serve as a prognostic signature. The predictive validity of this signature was determined using Kaplan-Meier and ROC curves, and was found to be acceptable in both the TCGA training, test and total dataset. The prognostic value of this signature was confirmed by univariate and multivariate Cox regression analysis, indicating its applicability as a prognostic factor. The immune cell infiltration was significantly associated with an immunosuppressive phenotype of TME in the high-risk group of patients; meanwhile, patients in the high-risk group had a lower TMB resulted in shorter survival. Notably, higher estimate scores and IC50 value for chemotherapy drugs were observed in the high-risk group, indicating poor response to immune therapy and chemotherapy.https://peerj.com/articles/18530.pdfCuproptosismiRNAPrognosisImmuneDrug sensitivityBladder cancer
spellingShingle Zhilei Zhang
Fang Liu
Yongbo Yu
Fei Xie
Tao Zhu
Prognosis and immune landscape of bladder cancer can be predicted using a novel miRNA signature associated with cuproptosis
PeerJ
Cuproptosis
miRNA
Prognosis
Immune
Drug sensitivity
Bladder cancer
title Prognosis and immune landscape of bladder cancer can be predicted using a novel miRNA signature associated with cuproptosis
title_full Prognosis and immune landscape of bladder cancer can be predicted using a novel miRNA signature associated with cuproptosis
title_fullStr Prognosis and immune landscape of bladder cancer can be predicted using a novel miRNA signature associated with cuproptosis
title_full_unstemmed Prognosis and immune landscape of bladder cancer can be predicted using a novel miRNA signature associated with cuproptosis
title_short Prognosis and immune landscape of bladder cancer can be predicted using a novel miRNA signature associated with cuproptosis
title_sort prognosis and immune landscape of bladder cancer can be predicted using a novel mirna signature associated with cuproptosis
topic Cuproptosis
miRNA
Prognosis
Immune
Drug sensitivity
Bladder cancer
url https://peerj.com/articles/18530.pdf
work_keys_str_mv AT zhileizhang prognosisandimmunelandscapeofbladdercancercanbepredictedusinganovelmirnasignatureassociatedwithcuproptosis
AT fangliu prognosisandimmunelandscapeofbladdercancercanbepredictedusinganovelmirnasignatureassociatedwithcuproptosis
AT yongboyu prognosisandimmunelandscapeofbladdercancercanbepredictedusinganovelmirnasignatureassociatedwithcuproptosis
AT feixie prognosisandimmunelandscapeofbladdercancercanbepredictedusinganovelmirnasignatureassociatedwithcuproptosis
AT taozhu prognosisandimmunelandscapeofbladdercancercanbepredictedusinganovelmirnasignatureassociatedwithcuproptosis